Literature DB >> 17525718

MN1 overexpression is an important step in the development of inv(16) AML.

C Carella1, J Bonten, S Sirma, T A Kranenburg, S Terranova, R Klein-Geltink, S Shurtleff, J R Downing, E C Zwarthoff, P P Liu, G C Grosveld.   

Abstract

The gene encoding the transcriptional co-activator MN1 is the target of the reciprocal chromosome translocation (12;22)(p13;q12) in some patients with acute myeloid leukemia (AML). In addition, expression array analysis showed that MN1 was overexpressed in AML specified by inv(16), in some AML overexpressing ecotropic viral integration 1 site (EVI1) and in some AML without karyotypic abnormalities. Here we describe that mice receiving transplants of bone marrow (BM) overexpressing MN1 rapidly developed myeloproliferative disease (MPD). This BM also generated myeloid cell lines in culture. By mimicking the situation in human inv(16) AML, forced coexpression of MN1 and Cbfbeta-SMMHC rapidly caused AML in mice. These findings identify MN1 as a highly effective hematopoietic oncogene and suggest that MN1 overexpression is an important cooperative event in human inv(16) AML.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525718     DOI: 10.1038/sj.leu.2404778

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  36 in total

1.  Gata1 regulates dendritic-cell development and survival.

Authors:  Laura Gutiérrez; Tatjana Nikolic; Thamar B van Dijk; Hamida Hammad; Nanda Vos; Monique Willart; Frank Grosveld; Sjaak Philipsen; Bart N Lambrecht
Journal:  Blood       Date:  2007-05-15       Impact factor: 22.113

2.  Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1.

Authors:  Yasuhiko Kamikubo; Ling Zhao; Mark Wunderlich; Takeshi Corpora; R Katherine Hyde; Thomas A Paul; Mondira Kundu; Lisa Garrett; Sheila Compton; Gang Huang; Linda Wolff; Yoshiaki Ito; John Bushweller; James C Mulloy; P Paul Liu
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

3.  Reintroduction of CEBPA in MN1-overexpressing hematopoietic cells prevents their hyperproliferation and restores myeloid differentiation.

Authors:  Ayten Kandilci; Gerard C Grosveld
Journal:  Blood       Date:  2009-06-26       Impact factor: 22.113

4.  Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling.

Authors:  A Sharma; H Yun; N Jyotsana; A Chaturvedi; A Schwarzer; E Yung; C K Lai; F Kuchenbauer; B Argiropoulos; K Görlich; A Ganser; R K Humphries; M Heuser
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

5.  MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.

Authors:  Simone S Riedel; Jessica N Haladyna; Matthew Bezzant; Brett Stevens; Daniel A Pollyea; Amit U Sinha; Scott A Armstrong; Qi Wei; Roy M Pollock; Scott R Daigle; Craig T Jordan; Patricia Ernst; Tobias Neff; Kathrin M Bernt
Journal:  J Clin Invest       Date:  2016-02-29       Impact factor: 14.808

6.  MN1 C-terminal truncation syndrome is a novel neurodevelopmental and craniofacial disorder with partial rhombencephalosynapsis.

Authors:  Christopher C Y Mak; Dan Doherty; Angela E Lin; Nancy Vegas; Megan T Cho; Géraldine Viot; Clémantine Dimartino; James D Weisfeld-Adams; Davor Lessel; Shelagh Joss; Chumei Li; Claudia Gonzaga-Jauregui; Yuri A Zarate; Nadja Ehmke; Denise Horn; Caitlin Troyer; Sarina G Kant; Youngha Lee; Gisele E Ishak; Gordon Leung; Amanda Barone Pritchard; Sandra Yang; Eric G Bend; Francesca Filippini; Chelsea Roadhouse; Nicolas Lebrun; Michele G Mehaffey; Pierre-Marie Martin; Benjamin Apple; Francisca Millan; Oliver Puk; Mariette J V Hoffer; Lindsay B Henderson; Ruth McGowan; Ingrid M Wentzensen; Steven Pei; Farah R Zahir; Mullin Yu; William T Gibson; Ann Seman; Marcie Steeves; Jill R Murrell; Sabine Luettgen; Elizabeth Francisco; Tim M Strom; Louise Amlie-Wolf; Angela M Kaindl; William G Wilson; Sara Halbach; Lina Basel-Salmon; Noa Lev-El; Jonas Denecke; Lisenka E L M Vissers; Kelly Radtke; Jamel Chelly; Elaine Zackai; Jan M Friedman; Michael J Bamshad; Deborah A Nickerson; Russell R Reid; Koenraad Devriendt; Jong-Hee Chae; Elliot Stolerman; Carey McDougall; Zöe Powis; Thierry Bienvenu; Tiong Y Tan; Naama Orenstein; William B Dobyns; Joseph T Shieh; Murim Choi; Darrel Waggoner; Karen W Gripp; Michael J Parker; Joan Stoler; Stanislas Lyonnet; Valérie Cormier-Daire; David Viskochil; Trevor L Hoffman; Jeanne Amiel; Brian H Y Chung; Christopher T Gordon
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

7.  Genetic abnormalities in acute myelogenous leukemia with normal cytogenetics.

Authors:  David Wald; Johanna M Vermaat; Gil Peleg; William Tse
Journal:  Curr Hematol Malig Rep       Date:  2008-04       Impact factor: 3.952

8.  Meningioma 1 is required for appropriate osteoblast proliferation, motility, differentiation, and function.

Authors:  Xiaoxue Zhang; Diane R Dowd; Meika C Moore; Tanya A Kranenburg; Magda A Meester-Smoor; Ellen C Zwarthoff; Paul N MacDonald
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

9.  Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

Authors:  Christian Langer; Guido Marcucci; Kelsi B Holland; Michael D Radmacher; Kati Maharry; Peter Paschka; Susan P Whitman; Krzysztof Mrózek; Claudia D Baldus; Ravi Vij; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

Review 10.  Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Clara D Bloomfield
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.